Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
no mention of adverse events)
SZU Top Ranking Project (86000000210)
Melissa T
US$ 20.54
US$ 28.42
US$ 24.80
US$ 21.69
US$ 23.66
US$ 25.84
US$ 20.93
US$ 21.62
US$ 28.44
US$ 21.71
